The market remained flat over the last week but is up 25% over the past year, with earnings forecast to grow by 17% annually. In light of these conditions, identifying stocks with strong financials and clear growth potential becomes crucial for investors seeking value. Although the term "penny stocks" may seem outdated, it still points to smaller or less-established companies that can offer significant opportunities; we've identified three such stocks that stand out for their financial strength and potential upside.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
ZJK Industrial (ZJK)	$2.80	$177.53M	✅ 3 ⚠️ 2 View Analysis >
WM Technology (MAPS)	$0.3756	$67.48M	✅ 2 ⚠️ 5 View Analysis >
LexinFintech Holdings (LX)	$2.07	$344.94M	✅ 3 ⚠️ 2 View Analysis >
Tuya (TUYA)	$2.25	$1.45B	✅ 4 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$3.76	$307.27M	✅ 3 ⚠️ 1 View Analysis >
Cricut (CRCT)	$3.94	$894.17M	✅ 2 ⚠️ 2 View Analysis >
Village Farms International (VFF)	$2.60	$305.15M	✅ 5 ⚠️ 1 View Analysis >
BAB (BABB)	$0.951175	$6.84M	✅ 2 ⚠️ 3 View Analysis >
Marine Petroleum Trust (MARP.S)	$5.00	$9.93M	✅ 2 ⚠️ 3 View Analysis >

Here's a peek at a few of the choices from the screener.

Whitehawk Therapeutics (WHWK)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Whitehawk Therapeutics, Inc. is a clinical-stage oncology therapeutics company focused on developing technologies for cancer treatments, with a market cap of $193.76 million.

Operations: Whitehawk Therapeutics, Inc. does not currently report any revenue segments as it is focused on developing cancer treatment technologies.

Market Cap: $193.76M

Whitehawk Therapeutics is a pre-revenue clinical-stage oncology company with a market cap of US$193.76 million, currently unprofitable and not expected to achieve profitability in the near term. The firm has no debt, with short-term assets significantly exceeding liabilities, but faces high volatility and recent insider selling. Recent developments include a significant private placement raising approximately US$87.5 million, indicating strong investor interest despite financial challenges. The company is advancing its ADC portfolio with promising preclinical data for HWK-007 and HWK-016 targeting cancer markers PTK7 and MUC16 respectively, though earnings are forecast to decline slightly over the next three years.

Caribou Biosciences (CRBU)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in CRISPR genome-editing technologies with a market cap of approximately $207.33 million.

Operations: Caribou Biosciences, Inc. has not reported any revenue segments.

Market Cap: $207.33M

Caribou Biosciences, Inc., with a market cap of US$207.33 million, is a pre-revenue biopharmaceutical firm focused on CRISPR genome-editing technologies. Despite being unprofitable and not expected to achieve profitability soon, the company has no debt and maintains sufficient cash runway for over a year under stable conditions. Recent developments include an RMAT designation from the FDA for its CB-011 therapy in multiple myeloma trials, potentially expediting regulatory processes. The firm reported reduced net losses in recent quarters and secured a non-exclusive license deal with Watchmaker Genomics to enhance sequencing workflows using CRISPR-Cas9 technology.

Zion Oil & Gas (ZNOG)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Zion Oil & Gas, Inc., along with its subsidiaries, is engaged in oil and gas exploration activities in Israel and has a market capitalization of $505.59 million.

Operations: Zion Oil & Gas, Inc. has not reported any revenue segments.

Market Cap: $505.59M

Zion Oil & Gas, Inc., with a market cap of US$505.59 million, remains pre-revenue and unprofitable, reporting a net loss of US$2.08 million for Q1 2026. The company holds short-term assets of US$13.9 million, exceeding both its short-term (US$2.5M) and long-term liabilities (US$1.6M), but faces less than a year of cash runway under current conditions. Despite reducing losses over five years by 11.9% annually and being debt-free, the auditor expressed doubts about its ability to continue as a going concern in their latest report filed on March 19, 2026.

Taking Advantage

• Click this link to deep-dive into the 356 companies within our US Penny Stocks screener.
• Contemplating Other Strategies? Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.